Expression and clinical significance of CLDN6, TRIM59 and CMTM6 in nasopharyngeal carcinoma

doi:10.11958/20242041

Abstract

Abstract:

Objective To investigate the expression and clinical significance of Claudin-6 (CLDN6), tripartite motif-containing protein 59 (TRIM59) and chemokine-like factor-like MARVEL transmembrane domain containing member 6 (CMTM6) in nasopharyngeal carcinoma (NPC) tissue. Methods A total of 135 NPC patients were selected as the study objects, and cancer tissue (observation group) and para-cancer tissue (control group) of all patients were collected. All patients were followed up for 3 years. According to the follow-up results, 93 surviving patients were included in the survival group and 42 dead patients were included in the death group. The mRNA expressions of CLDN6, TRIM59 and CMTM6 were determined by fluorescence quantitative PCR. Multivariate Cox regression was used to analyze the influencing factors of death in NPC patients. Kaplan-Meier method was used to analyze the relationship between the expression levels of CLDN6, TRIM59, CMTM6 and the prognosis of NPC patients. Results Compared with the control group, mRNA expressions of CLDN6, TRIM59 and CMTM6 were increased in the observation group (P<0.05). There were no significant differences in age, sex, body mass index, TNM stage, bone metastasis, smoking history, drinking history and hypertension history between the survival group and the death group. Compared with the survival group, the proportion of NPC family history and the mRNA expression of CLDN6, TRIM59 and CMTM6 in cancer tissue were increased in the death group (P < 0.05). Multivariate Cox regression analysis showed that the increased levels of CLDN6, TRIM59 and CMTM6 in cancer tissue were influential factors for death of NPC patients (P<0.05). According to the mean expression levels of CLDN6, TRIM59 and CMTM6 mRNA in cancer tissue, patients were divided into the low expression group and the high expression group. The 3-year survival rate of the high expression group was significantly lower than that of the low expression group (P<0.05). Conclusion The mRNA expressions of CLDN6, TRIM59 and CMTM6 in NPC tissue are significantly increased, which is a risk factor for death in NPC patients, and the mRNA expressions of CLDN6, TRIM59 and CMTM6 are correlated with the prognosis of patients.

Key words: nasopharyngeal carcinoma, tight junction protein Claudin-6, tripartite motif-containing protein 59, chemokine like factor superfamily 6

CLC Number:

R739.63

Figures/Tables 8

References 19

[1]	TANG L L, CHEN Y P, CHEN C B, et al. The Chinese Society of Clinical Oncology(CSCO)clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma[J]. Cancer Commun(Lond), 2021, 41(11):1195-1227. doi:10.1002/cac2.12218.
[2]	吴倩, 王意, 陈念, 等. 诱导化疗对鼻咽癌患者免疫功能及炎症指标的影响[J]. 天津医药, 2024, 52(4):397-402.
	WU Q, WANG Y, CHEN N, et al. Effect of induction chemotherapy on immune function and inflammatory indicators in patients with nasopharyngeal carcinoma[J]. Tianjin Med J, 2024, 52(4):397-402. doi:10.11958/20230792.
[3]	LI S, WAN X, DENG Y Q, et al. Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued[J]. Cancer Imaging, 2023, 23(1):14. doi:10.1186/s40644-023-00530-5.
[4]	JIN Q, QI D, ZHANG M, et al. CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation[J]. Cell Mol Biol Lett, 2024, 29(1):112. doi:10.1186/s11658-024-00629-y.
[5]	LIU T, JIANG L, BAI Q, et al. CLDN6 suppresses migration and invasion of MCF-7 and SKBR-3 breast cancer cells by blocking the SMAD/Snail/MMP-2/9 axis[J]. Bull Exp Biol Med, 2023, 175(3):376-381. doi:10.1007/s10517-023-05871-6.
[6]	王静怡, 马晓林. E3泛素连接酶三结构域蛋白59对非小细胞肺癌细胞增殖和侵袭的影响[J]. 解剖学研究, 2024, 46(2):139-144.
	WANG J Y, MA X L. Effects of E3 ubiquitin ligase TRIM59 on proliferation and invasion of non-small cell lung cancer cells[J]. Anatomy Research, 2024, 46(2):139-144. doi:10.20021/j.cnki.1671-0770.2024.02.08.
[7]	WANG H, LOU J, LIU H, et al. TRIM59 deficiency promotes M1 macrophage activation and inhibits colorectal cancer through the STAT1 signaling pathway[J]. Sci Rep, 2024, 14(1):16081. doi:10.1038/s41598-024-66388-0.
[8]	XING F, GAO H, CHEN G, et al. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer[J]. Mol Cancer, 2023, 22(1):6. doi:10.1186/s12943-023-01716-y.
[9]	LANG J, HU C, LU T, et al. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives[J]. Cancer Manag Res, 2019, 11:6365-6376. doi:10.2147/CMAR.S197544.
[10]	GIHBID A, TAWFIQ N, BENCHAKROUN N, et al. Epidemiological,clinicopathological and prognosis features of moroccan patients with nasopharyngeal carcinoma[J]. Asian Pac J Cancer Prev, 2023, 24(5):1477-1486. doi:10.31557/APJCP.2023.24.5.1477.
[11]	ITO Y, TAKASAWA A, TAKASAWA K, et al. Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma[J]. Cancer Sci, 2022, 113(4):1519-1530. doi:10.1111/cas.15284.
[12]	DONG Y, XU W, QI D, et al. CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/PTEN axis[J]. Cell Signal, 2023, 112:110930. doi:10.1016/j.cellsig.2023.110930.
[13]	栾婕, 刘霞, 李凤月, 等. 子宫内膜癌组织中紧密连接蛋白6、紧密连接蛋白9的表达及临床意义[J]. 中国性科学, 2022, 31(12):80-84.
	LUAN J, LIU X, LI F Y, et al. Expression and clinical significance of CLDN6 and CLDN9 in endometrial cancer[J]. Chinese Journal of Human Sexuality, 2022, 31(12):80-84. doi:10.3969/j.issn.1672-1993.2022.12.020.
[14]	FENG X, YANG G, ZHANG L, et al. TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer(CRC)cells' killing[J]. Invest New Drugs, 2022, 40(6):1244-1253. doi:10.1007/s10637-022-01306-7.
[15]	YANG W, CUI X, SUN D, et al. POU5F1 promotes the proliferation,migration,and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6[J]. Cell Death Dis, 2023, 14(12):802. doi:10.1038/s41419-023-06332-8.
[16]	王文忠, 周兰柱, 孙哲, 等. 下调三结构域蛋白59(TRIM59)阻断NF-κB信号通路抑制人鼻咽癌细胞的侵袭和迁移[J]. 细胞与分子免疫学杂志, 2022, 38(5):419-424.
	WANG W Z, ZHOU L Z, SUN Z, et al. Down-regulation of tripartite motif containing 59(TRIM59)blocks the NF-κB signaling pathway and inhibits the invasion and migration of nasopharyngeal carcinoma cells[J]. Chinese Journal of Cellular and Molecular Immunology, 2022, 38(5):419-424.doi:10.13423/j.cnki.cjcmi.009432.
[17]	杜姗姗, 叶双, 解龙川, 等. miR-124-3p. 2通过CMTM6调控口腔鳞状细胞癌细胞凋亡、铁死亡的机制研究[J]. 河北医科大学学报, 2023, 44(3):252-258,278.
	DU S S, YE S, XIE L C, et al. Study on the mechanism of miR-124-3p.2 regulating apoptosis and ferroptosis of oral squamous cell carcinoma cells by CMTM6[J]. Journal of Hebei Medical University, 2023, 44(3):252-258,278. doi:10.3969/j.issn.1007-3205.2023.03.002.
[18]	武川军, 彭丽娜, 冯志星, 等. 喉鳞状细胞癌组织中SEPT2、CMTM6表达及其与化疗敏感性的关系[J]. 国际检验医学杂志, 2023, 44(9):1075-1079.
	WU C J, PENG L N, FENG Z X, et al. Expression of SEPT2 and CMTM6 in laryngeal squamous cell carcinoma tissues and its relationship with chemotherapy sensitivity[J]. Int J Lab Med, 2023, 44(9):1075-1079. doi:10.3969/j.issn.1673-4130.2023.09.011.
[19]	谢刚, 成婧, 张俊萍. 趋化素样因子超家族成员在肿瘤中的研究进展[J]. 中国肺癌杂志, 2023, 26(1):46-51.
	XIE G, CHENG J, ZHANG J P, et al. Advances in the study of chemokine-like factor superfamily members in tumors[J]. Chin J Lung Cancer, 2023, 26(1):46-51. doi:10.3779/j.issn.1009-3419.2023.106.01.

组别	CLDN6	TRIM59	CMTM6
对照组	1.03±0.34	1.04±0.31	1.06±0.36
观察组	1.49±0.42	1.56±0.48	1.77±0.55
t	10.019^＊＊	10.801^＊＊	12.616^＊＊

组别	CLDN6	TRIM59	CMTM6
对照组	1.03±0.34	1.04±0.31	1.06±0.36
观察组	1.49±0.42	1.56±0.48	1.77±0.55
t	10.019^＊＊	10.801^＊＊	12.616^＊＊

组别	n	年龄/ 岁	性别（男/女）	BMI/ （kg/m²）	TNM分期（Ⅰ~Ⅱ/Ⅲ~Ⅳ）
生存组	93	52.11±5.67	68/25	22.15±3.28	52/41
死亡组	42	52.83±5.84	29/13	22.09±3.24	16/26
t或χ²		0.682	0.237	0.115	3.675
组别	骨转移（是/否）	吸烟史（有/无）	饮酒史（有/无）	高血压（有/无）	NPC家族史（有/无）
生存组	19/74	51/42	51/42	39/54	23/70
死亡组	11/31	19/23	19/23	14/28	18/24
χ²	0.555	1.068	1.068	0.898	4.495^＊

组别	n	年龄/ 岁	性别（男/女）	BMI/ （kg/m²）	TNM分期（Ⅰ~Ⅱ/Ⅲ~Ⅳ）
生存组	93	52.11±5.67	68/25	22.15±3.28	52/41
死亡组	42	52.83±5.84	29/13	22.09±3.24	16/26
t或χ²		0.682	0.237	0.115	3.675
组别	骨转移（是/否）	吸烟史（有/无）	饮酒史（有/无）	高血压（有/无）	NPC家族史（有/无）
生存组	19/74	51/42	51/42	39/54	23/70
死亡组	11/31	19/23	19/23	14/28	18/24
χ²	0.555	1.068	1.068	0.898	4.495^＊

组别	n	CLDN6	TRIM59	CMTM6
生存组	93	1.32±0.36	1.38±0.37	1.59±0.49
死亡组	42	1.86±0.54	1.96±0.62	2.18±0.67
t		5.988^＊＊	5.765^＊＊	5.792^＊＊